Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 148 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Tamoxifen Clear all

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Tamoxifen; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: PD-0332991 alone, Tamoxifen 60 mg, Tamoxifen 20 mg, PD-0332991 combination; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases, Tamoxifen, Estrogen Receptor Antagonist, Hormone Antagonists, Estrogens
Interventions: Tamoxifen, Placebo Oral Tablet; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Pegylated Liposomal Doxorubicin Hydrochloride, Tamoxifen; Procedure · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Cancer
Interventions: exemestane, Placebo; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 1,598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 150
States / cities: Huntsville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more

Conditions: Breast Cancer
Interventions: Raloxifene, Tamoxifen; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 35 Years and older · Female only
Enrollment: 19,747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 492
States / cities: Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 369 more

Conditions: Breast Neoplasms
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 30 Years to 70 Years · Female only
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Tamoxifen Citrate; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 559
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 356 more

Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Triple-negative Breast Cancer
Interventions: entinostat, anastrozole, diagnostic laboratory biomarker analysis, therapeutic conventional surgery; Drug · Other · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Brain and Central Nervous System Tumors
Interventions: tamoxifen citrate, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 237
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more

Conditions: Breast Cancer
Interventions: Tamoxifen Citrate, Placebo, Digital mammography, immunohistochemistry staining method, pharmacological study, laboratory biomarker analysis, protein expression analysis, pharmacogenomic studies, questionnaire administration, Fine needle aspiration, Quality of Life Assessment; Drug · Procedure · Other + 1 more
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 25 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • Aurora, Colorado + 9 more

Conditions: Menstruation Disturbances
Interventions: Tamoxifen, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer
Interventions: leuprolide, letrozole, zoledronic acid; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 4
States / cities: Denver, Colorado • Boston, Massachusetts • Newton, Massachusetts

Conditions: Breast Cancer
Interventions: letrozole; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 20
States / cities: Berkeley, California • Long Beach, California • Hollywood, Florida + 17 more

Conditions: Breast Carcinoma
Interventions: Biospecimen Collection, Electronic Health Record Review; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Fenretinide, Tamoxifen Citrate, Placebo; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: dextromethorphan hydrobromide, tamoxifen citrate, high performance liquid chromatography, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, fluorescence imaging; Drug · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Breast Cancer, Osteoporosis
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 35 Years to 50 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
Interventions: Tamoxifen, Placebo (for Tamoxifen); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Amyotrophic Lateral Sclerosis
Interventions: creatine, tamoxifen; Drug
Lead sponsor: Nazem Atassi; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: Kansas City, Kansas • Boston, Massachusetts • Worcester, Massachusetts + 6 more

Conditions: Breast Cancer
Interventions: comparative genomic hybridization, microarray analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis; Genetic · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Glioma
Interventions: Tamoxifen citrate, Bortezomib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: ARIMIDEX (anastrazole), NOLVADEX (tamoxifen); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 60 Years and older · Female only
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 13
States / cities: Santa Rosa, California • New Britain, Connecticut • Torrington, Connecticut + 10 more

Search by objective public record fields.

Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]

A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

The Ultrasound Study of Tamoxifen

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery

Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen

Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer

Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer

Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil

Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors

PROACT - Pre-Operative Arimidex Compared To Tamoxifen